BREA, CA – NuLiv Science announced the formal Novel Food status approval for its flagship ingredient, AstraGin®, a proprietary extract from Panax notoginseng and Astragalus membranaceus.
AstraGin® is marketed to support the absorption and bioavailability of key nutrients like amino acids, omegas, and folate, among others in the intestinal lumen. The extract can be found in a wide-range of dietary supplement formulas world-wide.
Within the data provided and after a few rounds of evaluation the Panel concluded that the Novel Food AstraGin® is safe for use in food supplements. With the approval, NuLiv Science now expands AstraGin® into the European market.
“It’s been a long, insightful journey and we’re very grateful to all the people who’ve been part of the process, from our science & production staff to Nutraveris, our consulting partner, to the wisdom of European Food Safety Agency. We’re excited to offer AstraGin® to the European market!”, shared Richard Wang, President at NuLiv Science.
In 2012, NuLiv Science received GRAS affirmed approval for AstraGin® along with a Natural Product Number (NPN) granted by Health Canada in 2017, which catapulted the ingredient into the Canadian dietary supplement market.
Josh Beaty, marketing director added, “This is an exciting time for the AstraGin® brand since we’ve been poised and ready to enter the European market. Over the past few years, we’ve been developing relationships with a number of key players in the industry and now we can help those brands build their dream products they’ve envisioned. We look forward to the expansion of AstraGin® across Europe.”
NuLiv Science is a full range ingredient supplier, early-stage developer of nutraceuticals and turnkey service provider to the dietary supplement and cosmeceutical industry. To learn more about AstraGin® visit www.nulivscience.com.
* * *